Helen Macpherson
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Helen Macpherson has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Pipingas
Centre for Mental Health and Brain Sciences, Swinburne University, Melbourne 3122, Australia
5 shared publications - Andrew Scholey
Swinburne University
4 shared publications - Elizabeth Harris
Centre for Human Psychopharmacology, Swinburne University of Technology, Hawthorn, Victoria, Australia
3 shared publications - Greg Kennedy
Centre for Mental Health and Brain Sciences, Swinburne University of Technology, Hawthorn, VIC, Australia
3 shared publications Andrew Pipingas
2 shared publications- Anne Marie Minihane
Norwich Medical School, University of East Anglia, NR4 7TJ, Norwich, United Kingdom
2 shared publications
Latest Publications
- Open Access
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e96922
Feasibility of a Co-Designed Personalized Cognitive Reablement Program Delivered via Digital Voice Assistants for Older Adults Living With Early-Stage Dementia or Mild Cognitive Impairment: Pilot Randomized Controlled Trial
Background: Home-based reablement programs have improved everyday functioning for people living with early-stage dementia or mild cognitive impairment (MCI), but the substantial time commitment required for delivery by health professionals has created a barrier to widespread implementation. Digital technology could facilitate delivery, but traditional devices such as smartphones and tablets present usability challenges for this population. We have co-designed a cognitive reablement program, VOICE-COG, that can deliver personalized interventions broadcast via voice-controlled digital voice assistants (DVAs). Objective: This pilot nonblinded randomized controlled trial examined the feasibility and potential effectiveness of VOICE-COG for older adults living with dementia or MCI to guide the design of a full-scale trial. Methods: Older adults (aged 60‐85 years) with a self-reported diagnosis of dementia or MCI (N=30) were recruited via Facebook or the StepUp-for Dementia Research database and randomized to either a DVA intervention (n=15) or control (n=15) group for 12 weeks. Each participant randomized to the intervention group and their care partner met with a psychologist via Zoom to select 2 or 3 personalized goals from the VOICE-COG program. The personalized program was input into the software (BuddyLink) by researchers for broadcast via a DVA (Amazon Alexa Show 8). Participants in the control group received enhanced usual care, consisting of treatment as usual, plus weekly informational emails. Primary feasibility outcomes were recruitment, retention, device-recorded adherence, and the System Usability Scale (SUS). Secondary outcomes were self-reported by the participant and care partner via web-based Qualtrics forms and included the Goal Attainment Scale–Light (GAS), changes in participant mood, cognition, and everyday functioning, and carer burden. Results: The recruitment rate was 86% (30/35) and the retention rate was 97% (29/30), with 1 participant in the intervention group lost to follow-up. Adherence to the VOICE-COG program ranged from 29% to 100% (mean 70%, SD 17%). The VOICE-COG program was rated as marginally acceptable (mean SUS score 56.3, SD 18.1). After 12 weeks, 60% (9/15) of the intervention group reported having met or exceeded their goals (GAS-Light t-score ≥50; mean 57.6, SD 15.4). The intervention group had a significantly higher increase in Multifactorial Memory Questionnaire–Strategy subscale score compared with control, mean difference 5.0 (95% CI 0.03-10.1, P =.049), representing a medium effect size ( d =0.55). There were no other significant differences between groups. Conclusions: This co-designed VOICE-COG program, delivered via DVAs, was feasible for older adults living with early-stage dementia or MCI, resulting in most participants meeting their reablement goals and increases in the use of memory strategies. System usability issues should be addressed in future adequately powered trials.
- 23 October 2026
- Published by JMIR Publications Inc. in JMIR Aging
- Vol. 9, e96922
Open AccessFeasibility of a Co-Designed Personalized Cognitive Reablement Program Delivered via Digital Voice Assistants for Older Adults Living With Early-Stage Dementia or Mild Cognitive Impairment: Pilot Randomized Controlled Trial
Background: Home-based reablement programs have improved everyday functioning for people living with early-stage dementia or mild cognitive impairment (MCI), but the substantial time commitment required for delivery by health professionals has created a barrier to widespread implementation. Digital technology could facilitate delivery, but traditional devices such as smartphones and tablets present usability challenges for this population. We have co-designed a cognitive reablement program, VOICE-COG, that can deliver personalized interventions broadcast via voice-controlled digital voice assistants (DVAs). Objective: This pilot nonblinded randomized controlled trial examined the feasibility and potential effectiveness of VOICE-COG for older adults living with dementia or MCI to guide the design of a full-scale trial. Methods: Older adults (aged 60‐85 years) with a self-reported diagnosis of dementia or MCI (N=30) were recruited via Facebook or the StepUp-for Dementia Research database and randomized to either a DVA intervention (n=15) or control (n=15) group for 12 weeks. Each participant randomized to the intervention group and their care partner met with a psychologist via Zoom to select 2 or 3 personalized goals from the VOICE-COG program. The personalized program was input into the software (BuddyLink) by researchers for broadcast via a DVA (Amazon Alexa Show 8). Participants in the control group received enhanced usual care, consisting of treatment as usual, plus weekly informational emails. Primary feasibility outcomes were recruitment, retention, device-recorded adherence, and the System Usability Scale (SUS). Secondary outcomes were self-reported by the participant and care partner via web-based Qualtrics forms and included the Goal Attainment Scale–Light (GAS), changes in participant mood, cognition, and everyday functioning, and carer burden. Results: The recruitment rate was 86% (30/35) and the retention rate was 97% (29/30), with 1 participant in the intervention group lost to follow-up. Adherence to the VOICE-COG program ranged from 29% to 100% (mean 70%, SD 17%). The VOICE-COG program was rated as marginally acceptable (mean SUS score 56.3, SD 18.1). After 12 weeks, 60% (9/15) of the intervention group reported having met or exceeded their goals (GAS-Light t-score ≥50; mean 57.6, SD 15.4). The intervention group had a significantly higher increase in Multifactorial Memory Questionnaire–Strategy subscale score compared with control, mean difference 5.0 (95% CI 0.03-10.1, P =.049), representing a medium effect size ( d =0.55). There were no other significant differences between groups. Conclusions: This co-designed VOICE-COG program, delivered via DVAs, was feasible for older adults living with early-stage dementia or MCI, resulting in most participants meeting their reablement goals and increases in the use of memory strategies. System usability issues should be addressed in future adequately powered trials.
- Open Access
- 11 October 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 154, 110339
Increasing engagement with a Mediterranean diet and walking program for healthy ageing: Participant and clinician experiences from the MedWalk trial
- 11 October 2026
- Published by Elsevier in Patient Education and Counseling
- Vol. 154, 110339
Open AccessIncreasing engagement with a Mediterranean diet and walking program for healthy ageing: Participant and clinician experiences from the MedWalk trial
- Open Access
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Behaviour change in a Mediterranean diet and walking intervention amongst older adults: The MedWalk trial
Background: Behaviour-change outcomes are often incompletely reported in multidomain trials. We evaluated behaviour change during a 12-month Mediterranean diet (MedDiet) and physical activity (PA) intervention.Participants and Setting: Adults aged 60 to 90 years without cognitive impairment, independently living in two Australian cities.Methods: n=83 participants (MedWalk group) were supported over 12 months to consume a MedDiet and engage in at least 150 minutes of moderate to vigorous PA (MVPA) per week. Control group participants (n=73) maintained habitual diet and PA. Four validated measures (MedWalk MedDiet Adherence Screener (MW-MEDAS), MedDiet Score, accelerometry-derived MVPA and MET minutes by International Physical Activity Questionnaire-elderly) were analysed separately and combined into a total adherence score to determine change in behaviour from baseline. Differences within and between groups were analysed at baseline, 6-months and 12-months using linear mixed effect modelling, controlling for predictors of attrition and baseline group differences.Results: Participants were 74% female, with a mean±SD age of 74.9 ± 5.9 years. After 12 months, MW-MEDAS had increased by an average of 3.3/14 points, and total adherence score by 1.4/8 points in the MedWalk group (p<.001), with no significant change in the control group. There were no significant changes in dietary behaviours in the control group, and MVPA declined in both groups at 6 months.Conclusions: The MedWalk intervention improved overall adherence among older adults over 12 months, driven by an increase in MedDiet adherence. PA did not increase, potentially due to high baseline PA or challenges in changing PA behaviours.
- 4 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBehaviour change in a Mediterranean diet and walking intervention amongst older adults: The MedWalk trial
Background: Behaviour-change outcomes are often incompletely reported in multidomain trials. We evaluated behaviour change during a 12-month Mediterranean diet (MedDiet) and physical activity (PA) intervention.Participants and Setting: Adults aged 60 to 90 years without cognitive impairment, independently living in two Australian cities.Methods: n=83 participants (MedWalk group) were supported over 12 months to consume a MedDiet and engage in at least 150 minutes of moderate to vigorous PA (MVPA) per week. Control group participants (n=73) maintained habitual diet and PA. Four validated measures (MedWalk MedDiet Adherence Screener (MW-MEDAS), MedDiet Score, accelerometry-derived MVPA and MET minutes by International Physical Activity Questionnaire-elderly) were analysed separately and combined into a total adherence score to determine change in behaviour from baseline. Differences within and between groups were analysed at baseline, 6-months and 12-months using linear mixed effect modelling, controlling for predictors of attrition and baseline group differences.Results: Participants were 74% female, with a mean±SD age of 74.9 ± 5.9 years. After 12 months, MW-MEDAS had increased by an average of 3.3/14 points, and total adherence score by 1.4/8 points in the MedWalk group (p<.001), with no significant change in the control group. There were no significant changes in dietary behaviours in the control group, and MVPA declined in both groups at 6 months.Conclusions: The MedWalk intervention improved overall adherence among older adults over 12 months, driven by an increase in MedDiet adherence. PA did not increase, potentially due to high baseline PA or challenges in changing PA behaviours.
- Open Access
- 2 August 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70783
Cognitive Reablement Using Digital Voice Assistants for People Living With Dementia or Mild Cognitive Impairment: A Co‐Design Study
Background: Digital health technology has the potential to increase access to home‐based reablement programmes for people living with dementia (PLwD) or mild cognitive impairment (MCI) to support everyday living. Digital Voice Assistants (DVAs) offer a possible solution to overcome usability issues with traditional technologies due to associated cognitive, motor and visual impairments. This paper describes the co‐design of a personalised reablement programme to be delivered via DVA. Methods: PLwD or MCI ( n = 9), their care partners ( n = 9) and health professionals ( n = 8) participated in the co‐design via online workshops and semi‐structured interviews. Phases 1–7 of the IDEAS (Integrate, Design, Assess and Share) framework guided this iterative process to develop a product for future feasibility testing. Consensus on essential functions and features was facilitated using the MoSCoW prioritisation method. Transcripts were analysed using a modified thematic framework to inform the reablement programme. Results: Thematic requirements of a cognitive reablement program to be delivered via DVA included (1) Daily Living (self‐care, household and cooking), (2) Activity Participation (leisure activities, home hobbies and ad hoc appointments), (3) Emotional Well‐being (social connection and coping strategies) and (4) technical requirements (activation, adaptable content, adherence, auditory processing, awareness and training). Conclusions: The IDEAS framework successfully facilitated meaningful engagement from PLwD or MCI, their care partners, and health professionals to integrate user insights and feedback to co‐design a personalised reablement program via DVA for subsequent pilot feasibility testing. Patient or Public Contribution: PLwD and/or MCI, and their care partners contributed by sharing lived experiences for researchers to gain insights; collaboratively identifying behaviours requiring support; creating ideas for solutions; feeding back on prototypes and prioritising program features and functions. Health professionals fed back improvements on prototypes, identifying potential barriers and solutions to implementation of the program.
- 2 August 2026
- Published by Wiley in Health Expectations
- Vol. 29 (4) , e70783
Open AccessCognitive Reablement Using Digital Voice Assistants for People Living With Dementia or Mild Cognitive Impairment: A Co‐Design Study
Background: Digital health technology has the potential to increase access to home‐based reablement programmes for people living with dementia (PLwD) or mild cognitive impairment (MCI) to support everyday living. Digital Voice Assistants (DVAs) offer a possible solution to overcome usability issues with traditional technologies due to associated cognitive, motor and visual impairments. This paper describes the co‐design of a personalised reablement programme to be delivered via DVA. Methods: PLwD or MCI ( n = 9), their care partners ( n = 9) and health professionals ( n = 8) participated in the co‐design via online workshops and semi‐structured interviews. Phases 1–7 of the IDEAS (Integrate, Design, Assess and Share) framework guided this iterative process to develop a product for future feasibility testing. Consensus on essential functions and features was facilitated using the MoSCoW prioritisation method. Transcripts were analysed using a modified thematic framework to inform the reablement programme. Results: Thematic requirements of a cognitive reablement program to be delivered via DVA included (1) Daily Living (self‐care, household and cooking), (2) Activity Participation (leisure activities, home hobbies and ad hoc appointments), (3) Emotional Well‐being (social connection and coping strategies) and (4) technical requirements (activation, adaptable content, adherence, auditory processing, awareness and training). Conclusions: The IDEAS framework successfully facilitated meaningful engagement from PLwD or MCI, their care partners, and health professionals to integrate user insights and feedback to co‐design a personalised reablement program via DVA for subsequent pilot feasibility testing. Patient or Public Contribution: PLwD and/or MCI, and their care partners contributed by sharing lived experiences for researchers to gain insights; collaboratively identifying behaviours requiring support; creating ideas for solutions; feeding back on prototypes and prioritising program features and functions. Health professionals fed back improvements on prototypes, identifying potential barriers and solutions to implementation of the program.
- Open Access
Implementing innovative technology promoting self-awareness of brain health and self-determination in obtaining a timely dementia diagnosis: protocol for a multimethods, concurrent, two-part observational study
Introduction Diagnosis in the early stages of dementia can lead to successful delay in associated cognitive decline. However, up to 76% of Australians diagnosed with dementia have already advanced beyond the early stage of disease. BrainTrack is an evidence-based mobile application (app) designed in Australia to promote brain health self-awareness, self-determination to promote help-seeking and, ultimately, a timelier dementia diagnosis. We will evaluate user experience, implementation and social return-on-investment outcomes of BrainTrack and will report dementia-related concerns, dementia literacy, knowledge, stigma and motivation for behaviour change and explore their associations with demographic characteristics. Methods and analysis A multimethods, concurrent, two-study observational design will be used. Study 1 will evaluate BrainTrack user experience and implementation outcomes, changes in users’ dementia literacy, dementia knowledge, perceptions of dementia-related stigma and help-seeking at five time points (baseline, 1, 3, 6 and 12 months). People residing in all states and territories of Australia will be recruited to the study via the BrainTrack app. Data collection will occur online and through teleconferencing. Approximately 1000 participants will complete all five surveys. Google Analytics data will measure adoption. App usage data will identify app use patterns. A sample of continuing app users (~n=80) and those who cease app use within 6 months (~n=20) will be interviewed to obtain in-depth information about their app use and help-seeking experience. Dementia Australia Helpline data will quantify help-seeking calls triggered by BrainTrack use. In Study 1, longitudinal outcomes will be analysed using mixed models. The economic and social value of BrainTrack will be assessed using social return on investment analysis. In Study 2, general practitioners (~n=20) currently practising in Australia will participate in semi-structured interviews conducted via online teleconferencing. Interviews will elicit perceptions of the usefulness of BrainTrack for initiating and facilitating discussions with patients about cognition and dementia. Qualitative data will be analysed thematically, followed by deductive analysis guided by the Theoretical Domains Framework. Ethics and dissemination This study has received Human Research Ethics Committee approval from Deakin University Human Research Ethics Committee (Study 1: HREC Reference Number 2022–220) and Deakin University Human Ethics Advisory Group, Faculty of Health (Study 2: Reference Number 202_2022). Informed consent will be obtained prior to participation, either verbally for interviews or online for surveys. Study findings will be published in peer-reviewed journals and communicated to key stakeholders.
Open AccessImplementing innovative technology promoting self-awareness of brain health and self-determination in obtaining a timely dementia diagnosis: protocol for a multimethods, concurrent, two-part observational study
Introduction Diagnosis in the early stages of dementia can lead to successful delay in associated cognitive decline. However, up to 76% of Australians diagnosed with dementia have already advanced beyond the early stage of disease. BrainTrack is an evidence-based mobile application (app) designed in Australia to promote brain health self-awareness, self-determination to promote help-seeking and, ultimately, a timelier dementia diagnosis. We will evaluate user experience, implementation and social return-on-investment outcomes of BrainTrack and will report dementia-related concerns, dementia literacy, knowledge, stigma and motivation for behaviour change and explore their associations with demographic characteristics. Methods and analysis A multimethods, concurrent, two-study observational design will be used. Study 1 will evaluate BrainTrack user experience and implementation outcomes, changes in users’ dementia literacy, dementia knowledge, perceptions of dementia-related stigma and help-seeking at five time points (baseline, 1, 3, 6 and 12 months). People residing in all states and territories of Australia will be recruited to the study via the BrainTrack app. Data collection will occur online and through teleconferencing. Approximately 1000 participants will complete all five surveys. Google Analytics data will measure adoption. App usage data will identify app use patterns. A sample of continuing app users (~n=80) and those who cease app use within 6 months (~n=20) will be interviewed to obtain in-depth information about their app use and help-seeking experience. Dementia Australia Helpline data will quantify help-seeking calls triggered by BrainTrack use. In Study 1, longitudinal outcomes will be analysed using mixed models. The economic and social value of BrainTrack will be assessed using social return on investment analysis. In Study 2, general practitioners (~n=20) currently practising in Australia will participate in semi-structured interviews conducted via online teleconferencing. Interviews will elicit perceptions of the usefulness of BrainTrack for initiating and facilitating discussions with patients about cognition and dementia. Qualitative data will be analysed thematically, followed by deductive analysis guided by the Theoretical Domains Framework. Ethics and dissemination This study has received Human Research Ethics Committee approval from Deakin University Human Research Ethics Committee (Study 1: HREC Reference Number 2022–220) and Deakin University Human Ethics Advisory Group, Faculty of Health (Study 2: Reference Number 202_2022). Informed consent will be obtained prior to participation, either verbally for interviews or online for surveys. Study findings will be published in peer-reviewed journals and communicated to key stakeholders.
- Open Access
- 14 January 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (2) , 1-15
Factors which influence social connection among cancer caregivers: an exploratory, interview study
Background/aims: Social connectedness is increasingly recognised as influencing health outcomes in cancer caregivers; however, there is little understanding of factors which foster feelings of social connectedness among caregivers when providing care. We sought to examine from the caregivers’ perspective, factors which contribute to perceived social connection when providing care to someone with cancer. Methods: Semi-structured interviews were conducted with 20 caregivers of people with cancer. Participants were recruited through social media and were eligible if they were aged 18 + years and had provided care to someone with cancer in the preceding 3 years. Data were analysed thematically using NVivo. Results: Following thematic analysis of interview data, six overarching themes emerged detailing caregivers’ experiences with social support, networks, and connectedness. Themes included: people in caregivers’ social networks and communication frequency, supportive communication with people in social networks, challenges with talking with others and seeking support, receiving instrumental support from social networks, impact of the carer role on friendships and community activities, and factors which fostered perceived connectedness. Conclusions: For caregivers of people with cancer, our qualitative findings suggest the importance of receiving emotional and instrumental support from social networks to cope with, and alleviate the stress and strain of providing care. Development and empirical testing of strategies and interventions that improve social support seeking and subsequently perceived connectedness among caregivers are recommended to improve health and wellbeing.
- 14 January 2025
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 33 (2) , 1-15
Open AccessFactors which influence social connection among cancer caregivers: an exploratory, interview study
Background/aims: Social connectedness is increasingly recognised as influencing health outcomes in cancer caregivers; however, there is little understanding of factors which foster feelings of social connectedness among caregivers when providing care. We sought to examine from the caregivers’ perspective, factors which contribute to perceived social connection when providing care to someone with cancer. Methods: Semi-structured interviews were conducted with 20 caregivers of people with cancer. Participants were recruited through social media and were eligible if they were aged 18 + years and had provided care to someone with cancer in the preceding 3 years. Data were analysed thematically using NVivo. Results: Following thematic analysis of interview data, six overarching themes emerged detailing caregivers’ experiences with social support, networks, and connectedness. Themes included: people in caregivers’ social networks and communication frequency, supportive communication with people in social networks, challenges with talking with others and seeking support, receiving instrumental support from social networks, impact of the carer role on friendships and community activities, and factors which fostered perceived connectedness. Conclusions: For caregivers of people with cancer, our qualitative findings suggest the importance of receiving emotional and instrumental support from social networks to cope with, and alleviate the stress and strain of providing care. Development and empirical testing of strategies and interventions that improve social support seeking and subsequently perceived connectedness among caregivers are recommended to improve health and wellbeing.
- Top Cited PapersOpen Access
- 13 June 2023
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 7 (1) , 699-714
The Impact of Loneliness and Social Isolation on Cognitive Aging: A Narrative Review
Social concepts such as loneliness and social isolation are fairly new factors that have been recently gaining attention as to their involvement in changes in cognitive function and association with dementia. The primary aim of this narrative review was to describe the current understanding of how loneliness and social isolation influence cognitive aging and how they are linked to dementia. Studies have shown that there is an association between loneliness, social isolation, and reduced cognitive function, in older adults, across multiple cognitive domains, as well as a heightened risk of dementia. Numerous changes to underlying neural biomechanisms including cortisol secretion and brain volume alterations (e.g., white/grey matter, hippocampus) may contribute to these relationships. However, due to poor quality research, mixed and inconclusive findings, and issues accurately defining and measuring loneliness and social isolation, more consistent high-quality interventions are needed to determine whether studies addressing loneliness and social isolation can impact longer term risk of dementia. This is especially important given the long-term impact of the COVID-19 pandemic on social isolation in older people is yet to be fully understood.
- 13 June 2023
- Published by SAGE Publications in Journal of Alzheimer's Disease Reports
- Vol. 7 (1) , 699-714
Top Cited PapersOpen AccessThe Impact of Loneliness and Social Isolation on Cognitive Aging: A Narrative Review
Social concepts such as loneliness and social isolation are fairly new factors that have been recently gaining attention as to their involvement in changes in cognitive function and association with dementia. The primary aim of this narrative review was to describe the current understanding of how loneliness and social isolation influence cognitive aging and how they are linked to dementia. Studies have shown that there is an association between loneliness, social isolation, and reduced cognitive function, in older adults, across multiple cognitive domains, as well as a heightened risk of dementia. Numerous changes to underlying neural biomechanisms including cortisol secretion and brain volume alterations (e.g., white/grey matter, hippocampus) may contribute to these relationships. However, due to poor quality research, mixed and inconclusive findings, and issues accurately defining and measuring loneliness and social isolation, more consistent high-quality interventions are needed to determine whether studies addressing loneliness and social isolation can impact longer term risk of dementia. This is especially important given the long-term impact of the COVID-19 pandemic on social isolation in older people is yet to be fully understood.
- Open Access
Effects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial
Objectives The aim of this preplanned secondary analysis of a 12-month randomised controlled trial was to investigate the effects of a multicomponent exercise programme combined with daily whey protein, calcium and vitamin D supplementation on cognition in men with prostate cancer treated with androgen deprivation therapy (ADT). Design 12-month, two-arm, randomised controlled trial. Setting University clinical exercise centre. Participants 70 ADT-treated men were randomised to exercise-training plus supplementation (Ex+ Suppl, n=34) or usual care (control, n=36). Intervention Men allocated to Ex + Suppl undertook thrice weekly resistance training with weight-bearing exercise training plus daily whey protein (25 g), calcium (1200 mg) and vitamin D (2000 IU) supplementation. Primary and secondary outcome measures Cognition was assessed at baseline, 6 and 12 months via a computerised battery (CogState), Trail-making test, Rey auditory-verbal learning test and Digit span. Data were analysed with linear mixed models and an intention-to-treat and prespecified per-protocol approach (exercise-training: ≥66%, nutritional supplement: ≥80%). Results Sixty (86%) men completed the trial (Ex + Suppl, n=31; control, n=29). Five (7.1%) men were classified as having mild cognitive impairment at baseline. Median (IQR) adherence to the exercise and supplement was 56% (37%–82%) and 91% (66%–97%), respectively. Ex + Suppl had no effect on cognition at any time. Conclusions A 12-month multicomponent exercise training and supplementation intervention had no significant effect on cognition in men treated with ADT for prostate cancer compared with usual care. Exercise training adherence below recommended guidelines does not support cognitive health in men treated with ADT for prostate cancer. Trial registration number Australian and New Zealand Clinical Trial Registry (ACTRN12614000317695, registered 25/03/2014) and acknowledged under the Therapeutic Goods Administration Clinical Trial Notification Scheme (CT-2015-CTN-03372-1 v1).
Open AccessEffects of a multicomponent resistance-based exercise program with protein, vitamin D and calcium supplementation on cognition in men with prostate cancer treated with ADT: secondary analysis of a 12-month randomised controlled trial
Objectives The aim of this preplanned secondary analysis of a 12-month randomised controlled trial was to investigate the effects of a multicomponent exercise programme combined with daily whey protein, calcium and vitamin D supplementation on cognition in men with prostate cancer treated with androgen deprivation therapy (ADT). Design 12-month, two-arm, randomised controlled trial. Setting University clinical exercise centre. Participants 70 ADT-treated men were randomised to exercise-training plus supplementation (Ex+ Suppl, n=34) or usual care (control, n=36). Intervention Men allocated to Ex + Suppl undertook thrice weekly resistance training with weight-bearing exercise training plus daily whey protein (25 g), calcium (1200 mg) and vitamin D (2000 IU) supplementation. Primary and secondary outcome measures Cognition was assessed at baseline, 6 and 12 months via a computerised battery (CogState), Trail-making test, Rey auditory-verbal learning test and Digit span. Data were analysed with linear mixed models and an intention-to-treat and prespecified per-protocol approach (exercise-training: ≥66%, nutritional supplement: ≥80%). Results Sixty (86%) men completed the trial (Ex + Suppl, n=31; control, n=29). Five (7.1%) men were classified as having mild cognitive impairment at baseline. Median (IQR) adherence to the exercise and supplement was 56% (37%–82%) and 91% (66%–97%), respectively. Ex + Suppl had no effect on cognition at any time. Conclusions A 12-month multicomponent exercise training and supplementation intervention had no significant effect on cognition in men treated with ADT for prostate cancer compared with usual care. Exercise training adherence below recommended guidelines does not support cognitive health in men treated with ADT for prostate cancer. Trial registration number Australian and New Zealand Clinical Trial Registry (ACTRN12614000317695, registered 25/03/2014) and acknowledged under the Therapeutic Goods Administration Clinical Trial Notification Scheme (CT-2015-CTN-03372-1 v1).
- Open Access
Does androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
Objectives We investigated whether there were differences in associations between cognition with muscle strength, fitness and function in men with prostate cancer (PCa) treated with, and without androgen deprivation therapy (ADT) and non-PCa controls. A secondary aim was to compare differences in the prevalence of cognitive impairment. Design This cross-sectional study compared 70 ADT-treated men with PCa aged 50–85 years to non-ADT-treated men (n=52) and non-PCa controls (n=70). Setting University clinical exercise laboratory. Interventions Nil. Primary and secondary outcome measures Standardised assessments were conducted for cognition (learning, memory, attention, processing speed and executive function), muscle strength (grip strength and leg press), fitness (400 m walk), gait speed (4 m walk) and dual-tasking mobility (timed-up-and-go with a cognitive task). Results ADT-treated men showed stronger associations between fitness and executive function and task switching relative to controls (both: p≤0.03). For both PCa groups (independent of ADT use), poorer dual-task mobility was more strongly associated with decreased psychomotor attention (both: p≤0.027) and global cognitive function (both: p≤0.031) compared with non-PCa controls. The overall prevalence of cognitive impairment was low (4%–13%) and did not differ between the groups. Conclusions The presence of PCa, with or without ADT treatment, did not increase the risk of cognitive impairment relative to non-PCa controls, yet did alter the associations between physical fitness and some measures of functional performance with certain cognitive domains. This highlights the importance of men with PCa maintaining fitness and functional capacity to optimise cognitive health. Trial registration number This study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12614000317695).
Open AccessDoes androgen deprivation impact associations between cognition and strength, fitness and function in community-dwelling men with prostate cancer? A cross-sectional study
Objectives We investigated whether there were differences in associations between cognition with muscle strength, fitness and function in men with prostate cancer (PCa) treated with, and without androgen deprivation therapy (ADT) and non-PCa controls. A secondary aim was to compare differences in the prevalence of cognitive impairment. Design This cross-sectional study compared 70 ADT-treated men with PCa aged 50–85 years to non-ADT-treated men (n=52) and non-PCa controls (n=70). Setting University clinical exercise laboratory. Interventions Nil. Primary and secondary outcome measures Standardised assessments were conducted for cognition (learning, memory, attention, processing speed and executive function), muscle strength (grip strength and leg press), fitness (400 m walk), gait speed (4 m walk) and dual-tasking mobility (timed-up-and-go with a cognitive task). Results ADT-treated men showed stronger associations between fitness and executive function and task switching relative to controls (both: p≤0.03). For both PCa groups (independent of ADT use), poorer dual-task mobility was more strongly associated with decreased psychomotor attention (both: p≤0.027) and global cognitive function (both: p≤0.031) compared with non-PCa controls. The overall prevalence of cognitive impairment was low (4%–13%) and did not differ between the groups. Conclusions The presence of PCa, with or without ADT treatment, did not increase the risk of cognitive impairment relative to non-PCa controls, yet did alter the associations between physical fitness and some measures of functional performance with certain cognitive domains. This highlights the importance of men with PCa maintaining fitness and functional capacity to optimise cognitive health. Trial registration number This study was registered with the Australian and New Zealand Clinical Trials Registry (ACTRN12614000317695).
- Open Access
- 11 December 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-13
The Moo’D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood
Background: Beta-casein is a major protein in cow’s milk, of which A1 and A2 are the most frequent variants. Recent evidence implicates A1 beta-casein consumption in mechanisms that are of potential importance to mental health, yet its possible effects on psychological endpoints remains unknown. The primary aim of the study is to evaluate the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood. Methods: ‘The Moo’D Study’ is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, will be measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes will include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness. Discussion: This study will advance our understanding of the possible impact of milk proteins on psychological distress in women as well as elucidate mechanisms underpinning any association. Given dairy products form a substantial component of traditional and Western diets, the implications of these findings are likely to be of clinical and public health importance. Trial registration: The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12618002023235. Registered on 17 December 2018.
- 11 December 2021
- Published by Springer Nature in Trials
- Vol. 22 (1) , 1-13
Open AccessThe Moo’D Study: protocol for a randomised controlled trial of A2 beta-casein only versus conventional dairy products in women with low mood
Background: Beta-casein is a major protein in cow’s milk, of which A1 and A2 are the most frequent variants. Recent evidence implicates A1 beta-casein consumption in mechanisms that are of potential importance to mental health, yet its possible effects on psychological endpoints remains unknown. The primary aim of the study is to evaluate the comparative effects of consumption of dairy products containing A2 beta-casein versus conventional dairy (i.e. containing both A1 and A2 beta-casein) on symptoms of psychological distress in women with low mood. Methods: ‘The Moo’D Study’ is a 16-week, superiority, 1:1 parallel group, triple-blinded, randomised controlled trial. Ninety women with low mood (Patient Health Questionnaire score ≥ 5) will be randomised to consume either A2 beta-casein only or conventional dairy products. The primary outcome, symptoms of psychological distress, will be measured by the 21-item Depression, Anxiety and Stress Scale. Secondary outcomes will include symptoms of depression, anxiety and stress, severity of low mood, cognition, gut microbiota composition, gut symptomatology, markers of immune function, gut inflammation, systemic metabolites, endothelial integrity and oxidative stress, body composition, perceived wellbeing, sleep, quality of life, resource use and cost-effectiveness. Discussion: This study will advance our understanding of the possible impact of milk proteins on psychological distress in women as well as elucidate mechanisms underpinning any association. Given dairy products form a substantial component of traditional and Western diets, the implications of these findings are likely to be of clinical and public health importance. Trial registration: The trial protocol has been prospectively registered with the Australia and New Zealand Clinical Trials Registry, ACTRN12618002023235. Registered on 17 December 2018.